yes the two trials are comparable. Enrolled Same advanced patients, metastatic pancreatic cancer. MPACT enrolled 860 patients randomised to gem + abrax combo or gem by itself. beyond PRs, will be good to see other measures such as disease control , time to progression and median survival at some stage. I’m certain ATX will release these in the future when the data more mature.
ATX Price at posting:
7.3¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)